Search Result
Results for "
amylin/calcitonin receptor
" in MedChemExpress (MCE) Product Catalog:
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P0090
-
|
Salmon calcitonin
|
CGRP Receptor
|
Cancer
|
|
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
|
-
-
- HY-P10798
-
|
LY-3841136
|
Amylin Receptor
|
Metabolic Disease
|
|
Eloralintide is an amylin receptor (AMYR) activator and long-acting peptide. Eloralintide selectively activates amylin receptors. Eloralintide is modified with a C20 fatty diacid moiety that binds to amylin receptors while retaining selectivity from calcitonin receptors. Eloralintide induces decreased appetite.Eloralintide reduces body weight. Eloralintide can be used for the research of obesity .
|
-
-
- HY-P3462
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
-
- HY-P1393
-
|
|
Amylin Receptor
|
Endocrinology
|
|
AC 187 is a potent and orally active amylin receptor antagonist with an IC50 of 0.48 nM and a Ki of 0.275 nM. AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 has neuroprotective effects .
|
-
-
- HY-P10745
-
|
ZP8396
|
Amylin Receptor
|
Metabolic Disease
|
|
Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research .
|
-
-
- HY-P11274A
-
|
Amycretin sodium; NN 9487 sodium
|
Amylin Receptor
Insulin Receptor
GCGR
|
Metabolic Disease
|
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
|
-
-
- HY-P10745A
-
|
ZP8396 acetate
|
Amylin Receptor
|
Metabolic Disease
|
|
Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research .
|
-
-
- HY-P10956
-
|
LY3541105
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
Colulintide (LY3541105) is an amylin-calcitonin dual receptor agonist with Amylin as its scaffold. Colulintide is applicable to research related to type 2 diabetes and obesity .
|
-
-
- HY-P1782
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
Calcitonin (8-32), salmon is a highly selective Amylin receptor antagonist. Calcitonin (8-32), salmon reverses the Amylin-mediated inhibition of glucose-induced insulin release, but has no effect on either glucagon release or somatostatin release. Calcitonin (8-32), salmon can be used for studies related to β-cell amylin .
|
-
-
- HY-P11274
-
|
Amycretin; NN 9487
|
Amylin Receptor
GCGR
Insulin Receptor
|
Metabolic Disease
|
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
|
-
-
- HY-179738
-
-
-
- HY-P1393A
-
|
|
Amylin Receptor
|
Endocrinology
|
|
AC 187 TFA is a potent and orally active amylin receptor antagonist with an IC50 of 0.48 nM and a Ki of 0.275 nM. AC 187 TFA shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 TFA has neuroprotective effects .
|
-
-
- HY-P11320
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .
|
-
-
- HY-117694
-
|
|
CGRP Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
MK-8825 is an orally active, selective CGRP receptor antagonist with a Ki value of 47 pM for human CGRP receptors and 17 nM for rat CGRP receptors. MK-8825 blocks CGRP-stimulated cAMP responses and exhibits competitive-like antagonism. MK-8825 can be used in the research of migraine and temporomandibular joint disorders .
|
-
-
- HY-P11269
-
-
-
- HY-P0090A
-
|
Salmon calcitonin acetate
|
CGRP Receptor
|
Cancer
|
|
Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .
|
-
-
- HY-P4863
-
|
|
CGRP Receptor
|
Neurological Disease
Metabolic Disease
|
|
Biotinyl-Amylin (human) is a biotin-labeled derivative of Amylin, amide, human (HY-P1070). Biotinyl-Amylin (human) acts as a competitive agonist for the Calcitonin Receptor (CTR) and for the Amylin receptors (AMY1, AMY2, and AMY3) formed by the association of CTR with RAMP1/2/3. By mimicking endogenous human amylin, Biotinyl-Amylin (human) binds to and activates CTR and AMY receptors, thereby initiating downstream signaling pathways involving cAMP, CREB, and ERK1/2, while retaining high-affinity receptor binding and activation capabilities. Biotinyl-Amylin (human) is primarily utilized in studies investigating the metabolic regulatory mechanisms underlying obesity and diabetes; it is also applicable to pharmacological research, receptor localization studies, and ligand-binding assays related to Amylin receptors in the context of Alzheimer's disease .
|
-
-
- HY-P0090S
-
|
Salmon calcitonin-13C6,15N4 TFA
|
CGRP Receptor
|
Metabolic Disease
|
|
Calcitonin- 13C6, 15N4 (salmon) (Salmon calcitonin- 13C6, 15N4) TFA is 13C and 15N-labeled Calcitonin (salmon) (HY-P0090). Calcitonin (salmon) , a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption .
|
-
-
- HY-P11586
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity .
|
-
-
- HY-P11830
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
|
-
-
- HY-P11843
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
TPM004 is an ultralong-acting, nonaggregating dual amylin (AMY3R) and calcitonin receptor (CTR) agonist with EC50 values of 0.5 and 0.7 pM. TPM004 induces weight loss, attenuates adiposity rebound, lowers glucose, and improves glucose homeostasis. TPM004 can be used for the research of obesity, diabetes .
|
-
-
- HY-P11588
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
KBP-042 is an orally active amylin receptor activator, a calcitonin receptor activator. KBP-042 induces sustained weight loss, reduces adipose tissue mass, lowers hepatic lipid deposition, increases plasma adiponectin, decreases plasma leptin, and reduces plasma glucose-dependent insulinotropic peptide levels. KBP-042 can be used for the research of obesity and insulin resistance .
|
-
-
- HY-P11665
-
-
-
- HY-P11584
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity .
|
-
-
- HY-186104
-
|
|
CGRP Receptor
Amylin Receptor
|
Metabolic Disease
|
AMYR/CTR agonist 1 (Compound 195) is a pancreatic amylin receptor and calcitonin receptor (AMYR/CTR) agonist with EC50 values for pancreatic amylin receptor and calcitonin receptor cAMP of 99.5 and 6.16 pM respectively. AMYR/CTR agonist 1 can be used in the research of diseases such as type 2 diabetes and obesity .
|
-
-
- HY-185229B
-
-
-
- HY-179728
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
Amylin agonist 1 (Example 239a) is a receptor 3 for pancreatic amyloid peptide (bAMY3R) agonist, and its EC50 for stimulating cAMP production in cells is 6.17 nM. Amylin agonist 1 is also a receptor for calcitonin (bCTR) agonist, with its EC50 being 8.58 nM. Amylin agonist 1 can be used for research on type 2 diabetes and obesity .
|
-
-
- HY-P11610
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
KBP-089 is a dual Amylin and Calcitonin Receptor agonist. KBP-089 reduces body weight, decreases adipose tissue mass and improves glucose tolerance in obese rats. KBP-089 also eliminates lipid accumulation in the liver and muscle, and ameliorates glycemic homeostasis and insulin sensitivity. KBP-089 is applicable to the research of diseases such as obesity and type 2 diabetes .
|
-
-
- HY-P11629
-
|
|
Amylin Receptor
CGRP Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis .
|
-
-
- HY-P11587
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
BGM1812 is a dual agonist of amylin (hAMY3R) (EC50 = 0.627 nM) and CGRP Receptor (hCTR) (EC50 = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0090
-
|
Salmon calcitonin
|
CGRP Receptor
|
Cancer
|
|
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
|
-
- HY-P10798
-
|
LY-3841136
|
Amylin Receptor
|
Metabolic Disease
|
|
Eloralintide is an amylin receptor (AMYR) activator and long-acting peptide. Eloralintide selectively activates amylin receptors. Eloralintide is modified with a C20 fatty diacid moiety that binds to amylin receptors while retaining selectivity from calcitonin receptors. Eloralintide induces decreased appetite.Eloralintide reduces body weight. Eloralintide can be used for the research of obesity .
|
-
- HY-P3462
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-P1393
-
|
|
Amylin Receptor
|
Endocrinology
|
|
AC 187 is a potent and orally active amylin receptor antagonist with an IC50 of 0.48 nM and a Ki of 0.275 nM. AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 has neuroprotective effects .
|
-
- HY-P10745
-
|
ZP8396
|
Amylin Receptor
|
Metabolic Disease
|
|
Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research .
|
-
- HY-P11274A
-
|
Amycretin sodium; NN 9487 sodium
|
Amylin Receptor
Insulin Receptor
GCGR
|
Metabolic Disease
|
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
|
-
- HY-P10745A
-
|
ZP8396 acetate
|
Amylin Receptor
|
Metabolic Disease
|
|
Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research .
|
-
- HY-P10956
-
|
LY3541105
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
Colulintide (LY3541105) is an amylin-calcitonin dual receptor agonist with Amylin as its scaffold. Colulintide is applicable to research related to type 2 diabetes and obesity .
|
-
- HY-P1782
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
Calcitonin (8-32), salmon is a highly selective Amylin receptor antagonist. Calcitonin (8-32), salmon reverses the Amylin-mediated inhibition of glucose-induced insulin release, but has no effect on either glucagon release or somatostatin release. Calcitonin (8-32), salmon can be used for studies related to β-cell amylin .
|
-
- HY-P11274
-
|
Amycretin; NN 9487
|
Amylin Receptor
GCGR
Insulin Receptor
|
Metabolic Disease
|
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
|
-
- HY-P1393A
-
|
|
Amylin Receptor
|
Endocrinology
|
|
AC 187 TFA is a potent and orally active amylin receptor antagonist with an IC50 of 0.48 nM and a Ki of 0.275 nM. AC 187 TFA shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 TFA has neuroprotective effects .
|
-
- HY-P11320
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .
|
-
- HY-P11269
-
-
- HY-P0090A
-
|
Salmon calcitonin acetate
|
CGRP Receptor
|
Cancer
|
|
Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .
|
-
- HY-P4863
-
|
|
CGRP Receptor
|
Neurological Disease
Metabolic Disease
|
|
Biotinyl-Amylin (human) is a biotin-labeled derivative of Amylin, amide, human (HY-P1070). Biotinyl-Amylin (human) acts as a competitive agonist for the Calcitonin Receptor (CTR) and for the Amylin receptors (AMY1, AMY2, and AMY3) formed by the association of CTR with RAMP1/2/3. By mimicking endogenous human amylin, Biotinyl-Amylin (human) binds to and activates CTR and AMY receptors, thereby initiating downstream signaling pathways involving cAMP, CREB, and ERK1/2, while retaining high-affinity receptor binding and activation capabilities. Biotinyl-Amylin (human) is primarily utilized in studies investigating the metabolic regulatory mechanisms underlying obesity and diabetes; it is also applicable to pharmacological research, receptor localization studies, and ligand-binding assays related to Amylin receptors in the context of Alzheimer's disease .
|
-
- HY-P0090S
-
|
Salmon calcitonin-13C6,15N4 TFA
|
CGRP Receptor
|
Metabolic Disease
|
|
Calcitonin- 13C6, 15N4 (salmon) (Salmon calcitonin- 13C6, 15N4) TFA is 13C and 15N-labeled Calcitonin (salmon) (HY-P0090). Calcitonin (salmon) , a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption .
|
-
- HY-P11586
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity .
|
-
- HY-P11830
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
|
-
- HY-P11843
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
TPM004 is an ultralong-acting, nonaggregating dual amylin (AMY3R) and calcitonin receptor (CTR) agonist with EC50 values of 0.5 and 0.7 pM. TPM004 induces weight loss, attenuates adiposity rebound, lowers glucose, and improves glucose homeostasis. TPM004 can be used for the research of obesity, diabetes .
|
-
- HY-P11588
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
KBP-042 is an orally active amylin receptor activator, a calcitonin receptor activator. KBP-042 induces sustained weight loss, reduces adipose tissue mass, lowers hepatic lipid deposition, increases plasma adiponectin, decreases plasma leptin, and reduces plasma glucose-dependent insulinotropic peptide levels. KBP-042 can be used for the research of obesity and insulin resistance .
|
-
- HY-P11665
-
-
- HY-P11584
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity .
|
-
- HY-P11610
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
KBP-089 is a dual Amylin and Calcitonin Receptor agonist. KBP-089 reduces body weight, decreases adipose tissue mass and improves glucose tolerance in obese rats. KBP-089 also eliminates lipid accumulation in the liver and muscle, and ameliorates glycemic homeostasis and insulin sensitivity. KBP-089 is applicable to the research of diseases such as obesity and type 2 diabetes .
|
-
- HY-P11629
-
|
|
Amylin Receptor
CGRP Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis .
|
-
- HY-P11587
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
BGM1812 is a dual agonist of amylin (hAMY3R) (EC50 = 0.627 nM) and CGRP Receptor (hCTR) (EC50 = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity .
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-P0090S
-
|
|
|
Calcitonin- 13C6, 15N4 (salmon) (Salmon calcitonin- 13C6, 15N4) TFA is 13C and 15N-labeled Calcitonin (salmon) (HY-P0090). Calcitonin (salmon) , a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: